Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication pertaining to Unaudited Financial Results of Q3FY2324-01-2023
24-01-2023
Gland Pharma profit declines 15% in Q3: What should you do with the stock?
Gland Pharma Q3: Revenue from operations for the quarter at Rs 938 crore declined 12% compared to year-ago period.24-01-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Call for the quarter and nine months ended December 31, 202223-01-2023
Q3FY23 Quarterly Result Announced for Gland Pharma Ltd.
Gland Pharma announced Q3FY23 results: Q3FY23: Financial summary: Revenue from operations for the nine months ended December 31, 2022, declined by 14% as compared to the corresponding period of the previous year due to significant business impact in the first quarter of the current financial year because of non-availability and long lead times for several processing and primary materials, softer offtake of few of our key products in the US and higher base of last year due to COVID related products sale. Revenue from operations during the quarter has declined by 12% as compared to the corresponding quarter of the previous year. Gross margin of the company improved during the quarter as compared to same quarter previous year and remained stable in nine months period of the year as compared to same period of previous financial year largely due to favourable geography mix and product mix. Marketwise Revenue: Core markets of US, Europe, Canada, Australia, and New Zealand accounted for 70% of revenue during Q3FY23, maintaining similar level of revenue contribution as compared to Q3FY22. Sale to US market is comprising of products sold to both US customers and Indian customers for US markets. For Q3FY23 direct sale to US customers Rs 5,179 million and to Indian customers for US markets was Rs 650 million, totalling Rs 5,829 million. During the quarter the Company launched 5 product SKUs. Rest of the world markets accounted for 21% of Q3FY23 revenue for the quarter. India market accounts for 9% of Q3FY23 revenue and witnessed the sequential recovery of business due to normalization of insulin production line. Research and Development: The total R&D; expense for Q3FY23 was Rs 512 million which is 5.5% of revenue. During nine months period of the current financial year, the company has incurred Rs 1,336 million in R&D; which is 4.7% of revenue. During Q3FY23, the Company filed 8 ANDAs and received 4 ANDA approvals. As on December 31, 2022, we along with our partners have 325 ANDA filings in the United States, of which 257 were approved and 68 pending approvals. Capex: Total Capex incurred during the quarter was Rs 427 million. During nine months, ended December 31, 2022, total capex incurred was Rs 1,253 million. The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad. The Company will be earmarking capital for further building on its Biosimilar CDMO facility Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “We closed this quarter Q3 FY23, with a revenue of Rs 9,383 Mn and a PAT of Rs 2,319 Mn. Challenging business environment, ongoing supply chain disruptions leading to production delays continue to impact our performance. We have received EIR from US FDA after the last audit at our Dundigal facility. Our continued focus on product quality and compliance differentiates us and provide confidence to our partners for long-term association. We also completed signing the share purchase agreement for the proposed acquisition of Cenexi. This is our first acquisition overseas and it is in line with Gland’s long-term growth objectives. It will enable Gland to increase its presence and to expand its product and service offering capability in Europe. Our new production lines in our sterile facility, in Pashamylaram, will support our product portfolio of complex and differentiated delivery formats. Amidst the tough business environment, we are taking all steps towards generating long-term stakeholder value.” Result PDF23-01-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q3FY23 Financial Results23-01-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Q3 FY23 (Quarter and Nine Months ended December 31, 2022) Financial Results23-01-2023
Gland Pharma Ltd - 543245 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022
The Board of Directors at its meeting held on January 23, 2023 has inter-alia approved the Unaudited financial results of the Company for the quarter and nine months ended December 31, 2022.23-01-2023
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Board Meeting Outcome For Board Meeting Outcome For Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022
The Board of Directors at its meeting held on January 23, 2023 has inter-alia approved the Unaudited financial results of the Company for the quarter and nine months ended December 31, 2022.23-01-2023
Gland Pharma Q3 PAT to Rs 2,729 cr: Nirmal Bang
Net Sales are expected to increase by 0.6 percent Y-o-Y (up 2.4 percent Q-o-Q) to Rs 10,696 crore, according to Nirmal Bang.17-01-2023
Drug firm Gland Pharma to fully acquire Europe-based Cenexi Group
Drug firm Gland Pharma on Friday said it has inked a pact with FPCI Sino French Midcap Fund to acquire 100 per cent stake in Europe-based Cenexi Group. Gland Pharma International PTE, a Singapore-based wholly owned subsidiary of the company, has entered into a share purchase agreement with FPCI Sino French Midcap Fund to fully acquire stake in Cenexi pursuant to the terms of the put option agreement inked in November last year. On November 29, 2022, the Hyderabad-based drug contract development and manufacturing company (CDMO) had entered into a put option agreement to acquire Cenexi Group for up to EUR 120 million (around Rs 1,015 crore), marking its foray into the international markets. Under the put option, an entity gets the right not obligation to sell a specified amount or stake at a predetermined price. Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of contract development and manufacturing organisation (CDMO) of pharmaceutical...06-01-2023